Page last updated: 2024-09-05

sorafenib and Desmoid

sorafenib has been researched along with Desmoid in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (47.37)24.3611
2020's10 (52.63)2.80

Authors

AuthorsStudies
Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ1
Errani, C; Mavrogenis, AF; Takahama, T; Tanaka, Y; Tsukamoto, S1
Al-Jazrawe, M; Alman, BA; Grünhagen, DJ; Sacchetti, A; Schut, AW; Sleijfer, S; Timbergen, MJM; Verhoef, C; Vriends, ALM; Wiemer, EAC1
Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A1
Androutsakos, T; Apostolidi, EA; Griniatsos, J; Karamouzis, MV; Papadakos, SP; Pergaris, A; Sarantis, P; Sougioultzis, S; Vallilas, C1
Le Deley, MC; Penel, N; Ryckewaert, T1
Orbach, D; Penel, N; Ryckewaert, T1
Davis, JT; Keskinyan, VS; Mater, DV; Robles, J; Thompson, M1
Bishop, AJ; Ratan, R; Roland, CL1
Al-Jahdhami, S; Burney, IA; Kakaria, AK1
Azem, F; Fouks, Y; Goaz, S; Hasson, Y; Malcov, M; Sheiman, V1
Benech, N; Saurin, JC; Walter, T1
Fernández-Ruiz, I1
Agaram, NP; Attia, S; Basch, E; Conry, RM; Deshpande, HA; Dueck, AC; Gounder, MM; Gupta, AA; Horvat, N; Lefkowitz, RA; Mahoney, MR; Maki, RG; Mazaheri, Y; Milhem, MM; Movva, S; Pishvaian, MJ; Ravi, V; Riedel, RF; Sabagh, T; Schwartz, GK; Schwartz, LH; Tap, WD; Van Tine, BA; Wright, JJ; Yamashita, R1
Wrighton, KH1
Kasper, B1
Batte, K; Braggio, D; Casadei, L; Jin, F; Koller, D; Lev, D; Lopez, G; Pollock, RE; Siva, N; Strohecker, AM; Welliver, M; Zewdu, A1
Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K1

Reviews

3 review(s) available for sorafenib and Desmoid

ArticleYear
Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
    Musculoskeletal surgery, 2023, Volume: 107, Issue:1

    Topics: Doxorubicin; Fibromatosis, Aggressive; Humans; Hydroxyurea; Imatinib Mesylate; Methotrexate; Sorafenib; Vinorelbine; Watchful Waiting

2023
Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management.
    American journal of clinical oncology, 2019, Volume: 42, Issue:12

    Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fibromatosis, Aggressive; France; Humans; Neoplasms, Connective Tissue; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome

2019
Desmoid Fibromatosis: Management in an Era of Increasing Options.
    Current oncology reports, 2021, 03-14, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Fibromatosis, Aggressive; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Watchful Waiting

2021

Trials

2 trial(s) available for sorafenib and Desmoid

ArticleYear
A cost analysis of sorafenib for desmoid tumors.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:3

    Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; United States

2023
Sorafenib for Advanced and Refractory Desmoid Tumors.
    The New England journal of medicine, 2018, 12-20, Volume: 379, Issue:25

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Double-Blind Method; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Rate; Young Adult

2018

Other Studies

14 other study(ies) available for sorafenib and Desmoid

ArticleYear
In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2022, Volume: 48, Issue:7

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Autophagy; Ferroptosis; Fibromatosis, Aggressive; Humans; Sorafenib

2022
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 186

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fibromatosis, Aggressive; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult

2023
Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management.
    The American journal of case reports, 2023, Oct-09, Volume: 24

    Topics: Aged; Female; Fibromatosis, Aggressive; Humans; Liver Neoplasms; Sorafenib; Tamoxifen

2023
[Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
    Bulletin du cancer, 2020, Volume: 107, Issue:3

    Topics: Adult; Age Factors; Antineoplastic Agents; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Vinblastine

2020
Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.
    Pediatric hematology and oncology, 2020, Volume: 37, Issue:5

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Cyclooxygenase 2; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Risk Factors; Sorafenib; Treatment Outcome

2020
Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis.
    Sultan Qaboos University medical journal, 2021, Volume: 21, Issue:2

    Topics: Fibromatosis, Aggressive; Humans; Neoplasm Recurrence, Local; Sorafenib

2021
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
    Reproductive biomedicine online, 2021, Volume: 43, Issue:4

    Topics: Abdominal Neoplasms; Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Female; Fertility Preservation; Fibromatosis, Aggressive; Humans; Oocyte Retrieval; Pregnancy; Preimplantation Diagnosis; Retrospective Studies; Sorafenib; Young Adult

2021
Desmoid Tumors and Celecoxib with Sorafenib.
    The New England journal of medicine, 2017, 06-29, Volume: 376, Issue:26

    Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2017
Targeting PCSK9 to reduce residual risk in ACS.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:1

    Topics: Cholesterol, LDL; Fibromatosis, Aggressive; Humans; Proprotein Convertase 9; Sorafenib

2019
Desmoid tumours stalled by sorafenib.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:4

    Topics: Clinical Trials, Phase III as Topic; Double-Blind Method; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Progression-Free Survival; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome; Tumor Burden

2019
Desmoid Tumors Respond to Sorafenib.
    Cancer discovery, 2019, Volume: 9, Issue:3

    Topics: Fibromatosis, Aggressive; Humans; Progression-Free Survival; Sorafenib

2019
Desmoid tumor: A focus set on a challenging but understudied rare disease.
    Cancer, 2019, 08-01, Volume: 125, Issue:15

    Topics: Autophagy; Fibromatosis, Aggressive; Humans; Rare Diseases; Sorafenib

2019
Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.
    Cancer, 2019, 08-01, Volume: 125, Issue:15

    Topics: Antineoplastic Agents; Autophagy; Female; Fibromatosis, Aggressive; Humans; Male; Sorafenib

2019
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-15, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Watchful Waiting; Young Adult

2011